Advertisement

Topics

Teva Pharmaceutical Industries Limited (TEVA) Stock Rating Reaffirmed by Credit Suisse Group

09:55 EST 8 Nov 2017 | Topix

's stock had its "underperform" rating reiterated by Credit Suisse Group in a report issued on Monday. They presently have a $8.00 target price on the stock, down from their previous target price of $14.00.

Original Article: Teva Pharmaceutical Industries Limited (TEVA) Stock Rating Reaffirmed by Credit Suisse Group

NEXT ARTICLE

More From BioPortfolio on "Teva Pharmaceutical Industries Limited (TEVA) Stock Rating Reaffirmed by Credit Suisse Group"

Advertisement
Quick Search
Advertisement
Advertisement